Stockpolly
Search
Delisting risk
FBLG · NASDAQ · Biotechnology

FibroBiologics (FBLG)

Develops allogeneic fibroblast therapies for diabetic foot ulcers and other chronic diseases.

$1.89
Pre-market−0.05 (−2.82%)
At close$1.94(−8.06%)
Watchlist

In millions of USD, except per-share figures

In millionsQ3 FY23Sep 2023Q4 FY23Dec 2023Q1 FY24Mar 2024Q2 FY24Jun 2024Q3 FY24Sep 2024Q4 FY24Dec 2024Q1 FY25Mar 2025Q2 FY25Jun 2025Q3 FY25Sep 2025Q4 FY25Dec 2025Q1 FY26Mar 2026Q2 FY26Jun 2026
Cost of revenue000000000000
Gross profit000000000000
223334545254
Research & development111111223132
122222322222
General & administrative122222322222
Other expenses000000000000
Operating income−2−2−3−3−3−4−5−4−5−3−5−4
0−7−543100−1−100
Interest income000000000000
Interest expense000000000000
Other non-operating income075−4−3−1001000
Income before tax−2−10−81−1−3−5−5−6−3−5−4
Net income from continuing operations−2−10−81−1−3−5−5−6−3−5−4
Net income−2−10−81−1−3−5−5−6−3−5−4
EPS, basic−$1.35−$6.20−$5.40$0.60−$0.20−$1.78−$2.80−$2.40−$2.60−$0.98−$1.33−$1.09
EPS, diluted−$1.35−$6.20−$5.40$0.60−$0.20−$1.78−$2.80−$2.40−$2.60−$0.98−$1.33−$1.09
Weighted average shares, basic222222222344
Weighted average shares, diluted222222222344
EBITDA−2−10−810−3−5−4−6−3−5−4
Depreciation & amortization000000000000
EBIT−2−10−810−3−5−5−6−3−5−4